- Home
- SGBX vs PCSA Comparison
SGBX vs PCSA Comparison
Compare SGBX & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGBX
- PCSA
- Stock Information
- Founded
- SGBX 2007
- PCSA 2011
- Country
- SGBX United States
- PCSA United States
- Employees
- SGBX N/A
- PCSA N/A
- Industry
- SGBX RETAIL: Building Materials
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- SGBX Consumer Discretionary
- PCSA Health Care
- Exchange
- SGBX Nasdaq
- PCSA Nasdaq
- Market Cap
- SGBX 2.7M
- PCSA 3.3M
- IPO Year
- SGBX 2017
- PCSA N/A
- Fundamental
- Price
- SGBX $0.65
- PCSA $0.22
- Analyst Decision
- SGBX
- PCSA Strong Buy
- Analyst Count
- SGBX 0
- PCSA 1
- Target Price
- SGBX N/A
- PCSA $6.00
- AVG Volume (30 Days)
- SGBX 1.6M
- PCSA 46.5M
- Earning Date
- SGBX 06-13-2025
- PCSA 08-12-2025
- Dividend Yield
- SGBX N/A
- PCSA N/A
- EPS Growth
- SGBX N/A
- PCSA N/A
- EPS
- SGBX N/A
- PCSA N/A
- Revenue
- SGBX $4,574,857.00
- PCSA N/A
- Revenue This Year
- SGBX $1,628.82
- PCSA N/A
- Revenue Next Year
- SGBX N/A
- PCSA N/A
- P/E Ratio
- SGBX N/A
- PCSA N/A
- Revenue Growth
- SGBX N/A
- PCSA N/A
- 52 Week Low
- SGBX $0.30
- PCSA $0.15
- 52 Week High
- SGBX $3.75
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- SGBX 45.31
- PCSA 44.28
- Support Level
- SGBX $0.60
- PCSA $0.20
- Resistance Level
- SGBX $0.97
- PCSA $0.33
- Average True Range (ATR)
- SGBX 0.12
- PCSA 0.09
- MACD
- SGBX -0.03
- PCSA -0.01
- Stochastic Oscillator
- SGBX 19.90
- PCSA 6.53
About SGBX Safe & Green Holdings Corp.
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).